Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01567722 · ADVERSE EVENTS

Adverse events

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies · Source last updated 2023-03-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Adverse events data was not collected for this study..
Other-event reporting threshold
0%

As a laboratory study involving only sample collection through routine clinical care and data abstraction, no adverse events was collected for this study.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
HIV-positive Diffuse Large B-cell Lymphoma Cases

Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.

0 / 00 / 00 / 0
HIV-positive Lung Cancer Cases

Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.

0 / 00 / 00 / 0
HIV Positive Cervical Cancer Cases

Tissue collection for genomic sequencing from persons with a diagnosis of HIV and cervical cancer.

0 / 00 / 00 / 0

Group identifiers: EG000: HIV-positive Diffuse Large B-cell Lymphoma Cases · EG001: HIV-positive Lung Cancer Cases · EG002: HIV Positive Cervical Cancer Cases

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      As a laboratory study involving only sample collection through routine clinical care and data abstraction, no adverse events was collected for this study.
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        HIV-positive Diffuse Large B-cell Lymphoma Cases
      2. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        HIV-positive Lung Cancer Cases
      3. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Tissue collection for genomic sequencing from persons with a diagnosis of HIV and cervical cancer.
        id
        EG002
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        HIV Positive Cervical Cancer Cases
      frequency Threshold
      0
      time Frame
      Adverse events data was not collected for this study..

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice